In recent years, the efficiency of NMPA innovative drug approval has significantly improved, greatly increasing the supply of innovative drugs in the Chinese market. Among the winners, there are both foreign-funded pharmaceutical companies that are increasingly placing greater emphasis on betting in the Chinese market, as well as veteran biotechnology companies that have been independently developing for over a decade, finally struggling to survive. In addition, there are also some start-up biotechnology companies that use licenses to enter and accelerate the rapid listing of overseas new drugs in China. Company.

When a product is not launched, the PK between similar biotech products can be reflected in multiple aspects such as clinical strategy, development progress, indication layout, and business prospects. After the product is launched, its sales performance can be described as a test of the past "story". Unique standard. With the disclosure of the 2021 semi annual report, more and more innovative drugs have also submitted preliminary answers after entering the commercialization stage.